

CAPLIN POINT LABORATORIES LIMITED
Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017
CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2015

Part I Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Three months ended			Nine months ended		Year ended
	Mar 31, 2015	Dec 31, 2014	Mar 31, 2014	Mar 31, 2015	Mar 31, 2014	June 30, 2014
	Rs. In Lakhs					
1 Income						Rs. In Lakhs
a. Net Sales/ income from operations (Net of Excise Duty)						
b. Foreign Exchange Fluctuation Gain	5,818.21	5,518.29	3,832.48	16,618.53	11,526.04	15,806.18
c. Share of profits in LLP	-	-	146.74	-	-	-
d. Total	273.52	227.84	159.48	648.92	524.54	833.62
	6,091.73	5,746.13	4,138.70	17,267.45	12,050.58	16,639.80
2 Expenditure						
a. Cost of materials consumed						
b. Purchase of Stock-in-Trade	928.57	983.99	516.51	2,572.98	1,828.71	2,460.65
c. Change in inventories of Finished Goods, work in progress and stock in trade	2,296.65	2,056.44	1,895.78	6,844.06	5,559.59	7,581.04
d. Employees benefit expenses	(7.92)	91.42	8.12	34.66	5.83	(68.39)
e. Depreciation	463.41	442.65	332.86	1,302.67	887.78	1,237.70
f. Amortisation of Intangible Assets	136.21	183.10	86.46	508.39	180.45	335.89
g. Foreign Exchange Fluctuation Loss	-	5.49	1.90	10.89	5.40	8.00
h. Research and Development Expenses	51.13	138.57	-	189.70	311.54	307.61
i. Other Expenditure	154.12	135.01	42.95	411.95	92.72	208.00
j. Total	772.23	665.17	348.27	2,107.40	926.76	1,553.24
3 Profit(+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)	4,794.40	4,701.84	3,232.85	13,982.70	9,798.78	13,623.74
4 Other Income	1,297.33	1,044.29	905.85	3,284.75	2,251.80	3,016.06
5 Profit(+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)	62.43	73.38	134.58	190.24	265.10	333.72
6 Finance cost	1,359.76	1,117.67	1,040.43	3,474.99	2,516.90	3,349.78
7 Profit(+)/Loss(-) from Ordinary Activities after finance cost but before exceptional items (5-6)	3.90	4.54	1.52	13.18	6.59	11.84
8 Exceptional items	1,355.86	1,113.13	1,038.91	3,461.81	2,510.31	3,337.94
9 Profit(+)/Loss(-) from Ordinary Activities before Tax (7-8)	-	-	-	-	-	-
10 Provision for Taxation	1,355.86	1,113.13	1,038.91	3,461.81	2,510.31	3,337.94
Provision for Taxation - earlier years	231.00	172.00	145.00	593.00	390.00	500.00
Deferred Tax Provision	-	-	-	(80.00)	-	-
Mat Credit Entitlement	65.00	30.00	207.40	125.00	249.40	274.40
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	-	-	-	-	-	-
12 Extraordinary Item (net of tax expense)	1,059.86	911.13	686.51	2,823.81	1,870.91	2,563.54
13 Net Profit(+)/Loss(-) for the period (11-12)	1,059.86	911.13	686.51	2,823.81	1,870.91	2,563.54
14 Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00	1,511.00
15 Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	4,343.63
16 Earnings/(Loss) Per Share (EPS) (Not annualised)						
(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	7.01	6.03	4.54	18.69	12.38	16.97
(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	7.01	6.03	4.54	18.69	12.38	16.97

Part II	Select information for the Quarter ended 31st March 2015					
	Three months ended			Six months ended		Year ended
	Unaudited	Unaudited	Unaudited	Unaudited		Audited
	Mar 31, 2015	Dec 31, 2014	Mar 31, 2014	Mar 31, 2014		June 30, 2014
A	PARTICULARS OF SHARE HOLDING					
17	Public Shareholding					
	- Number of Shares	48,63,247	62,39,247	62,39,247	48,63,247	62,39,247
	- Percentage of Shareholding	32.19%	41.29%	41.29%	32.19%	41.29%
18	Promoters and promoter group Shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of Shares	1,02,46,753	88,70,753	88,70,753	1,02,46,753	88,70,753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	67.81%	58.71%	58.71%	67.81%	58.71%

B	Particulars	3 months ended 31-3-2015
	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	Nil
	Received during the quarter	46
	Disposed of during the quarter	46
	Remaining unresolved at the end of the quarter	Nil

otes :

- 1) The Company operates in one segment only.
- 2) The above Standalone unaudited financial results were considered and recommended by the Audit Committee of the Board and have been approved by the Board of Directors at its meeting held on 12th May 2015
- 3) The statutory auditors have carried out a limited review of the results for the quarter ended 31st March 2015
- 4) The consolidated financial results include the financial results of Argus Salud Pharma LLP in which controlling interest is held by the company.
- 5) Prior year / period figures are regrouped / rearranged wherever necessary.

Place : Chennai
Date : 12.05.2015


Dr. Sridhar Ganesan
Managing Director

CAPLIN POINT LABORATORIES LIMITED
Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017
CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2015

Part I Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Three months ended			Nine months ended		Year ended
	Mar 31,	Dec 31,	Mar 31,	Mar 31,	Mar 31,	June 30,
	2015	2014	2014	2015	2014	2014
	Rs. In Lakhs					Rs. In Lakhs
1 Income						
a. Net Sales/ income from operations (Net of Excise Duty)	6,361.95	6,088.31	4,140.31	18,164.27	12,513.18	17,308.89
b. Foreign Exchange Fluctuation Gain	-	-	158.30	-	-	-
c. Total	6,361.95	6,088.31	4,298.61	18,164.27	12,513.18	17,308.89
2 Expenditure						
a. Cost of materials consumed	1,158.84	1,131.10	744.57	3,151.57	2,480.21	3,306.15
b. Purchase of Stock-in-Trade	2,180.88	2,136.34	1,714.28	6,758.76	5,053.03	7,048.34
c. Change in inventories of Finished Goods, work in progress and stock in trade	(9.39)	113.57	(18.80)	74.67	25.80	(95.61)
d. Employees benefit expenses	478.22	449.28	341.44	1,334.42	915.62	1,275.68
e. Depreciation	138.71	185.60	89.07	515.90	187.85	345.63
f. Amortisation of Intangible Assets	-	5.49	1.90	10.89	5.40	8.00
g. Foreign Exchange Fluctuation Loss	47.05	140.19	-	187.24	310.91	307.61
h. Research and Development Expenses	154.12	135.01	42.95	411.95	92.72	208.00
i. Other Expenditure	814.84	704.81	389.27	2,227.01	1,034.90	1,697.23
j. Total	4,963.26	5,001.39	3,304.68	14,672.41	10,106.44	14,101.03
3 Profit(+)/Loss(-) from Operations before other income and finance cost and exceptional items (1-2)	1,398.69	1,086.92	993.93	3,491.86	2,406.74	3,207.86
4 Other Income	69.71	80.53	143.03	211.79	287.90	373.48
5 Profit(+)/Loss(-) from ordinary activities before finance cost and exceptional items (3+4)	1,468.40	1,167.45	1,136.96	3,703.65	2,694.64	3,581.34
6 Finance cost	3.95	4.60	1.62	13.38	6.92	12.26
7 Profit(+)/Loss(-) from Ordinary Activities after finance cost but before exceptional items (5-6)	1,464.45	1,162.85	1,135.34	3,690.27	2,687.72	3,569.08
8 Exceptional items	-	-	-	-	-	-
9 Profit(+)/Loss(-) from Ordinary Activities before Tax (7-8)	1,464.45	1,162.85	1,135.34	3,690.27	2,687.72	3,569.08
10 Provision for Taxation	336.00	217.00	216.40	803.00	546.40	701.40
Provision for Taxation - earlier years	-	-	-	(80.00)	-	-
Deferred Tax Provision	65.00	30.00	207.40	125.00	249.40	274.40
Mat Credit Entitlement	-	-	-	-	-	-
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	1,063.45	915.85	711.54	2,842.27	1,891.92	2,593.28
12 Extraordinary Item (net of tax expense)	-	-	-	-	-	-
13 Net Profit(+)/Loss(-) for the period before minority interest (11-12)	1,063.45	915.85	711.54	2,842.27	1,891.92	2,593.28
14 Minority Interest	2.76	2.30	1.61	6.55	5.30	8.42
15 Net Profit(+)/Loss(-) for the period after minority interest (13-14)	1,060.69	913.55	709.93	2,835.72	1,886.62	2,584.86
16 Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511	1,511	1,511	1,511.00	1,511.00	1,511.00
17 Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	4,289.48
18 Earnings/(Loss) Per Share (EPS) (Not annualised)						
(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	7.02	6.05	4.70	18.77	12.49	17.11
(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	7.02	6.05	4.70	18.77	12.49	17.11

Part II	Select information for the Quarter ended 31st March 2015							Select information for the Quarter ended 31st March 2015				
	Three months ended			Nine months ended		Year ended	Three months ended			Nine months ended		Year ended
	Unaudited	Unaudited	Unaudited	Unaudited		Audited	Unaudited	Unaudited	Unaudited	Unaudited		Audited
	Mar 31,	Dec 31,	Mar 31,	Mar 31,		June 30,	Mar 31,	Dec 31,	Mar 31,	Mar 31,		June 30,
	2015	2014	2014	2015	2014	2014	2015	2014	2014	2015	2014	2014
A	PARTICULARS OF SHARE HOLDING											
19	Public Shareholding											
	- Number of Shares											
	48,63,247	62,39,247	62,39,247	48,63,247	62,39,247	62,39,247	48,63,247	62,39,247	62,39,247	48,63,247	62,39,247	62,39,247
	- Percentage of Shareholding											
	32.19%	41.29%	41.29%	32.19%	41.29%	41.29%	32.19%	41.29%	41.29%	32.19%	41.29%	41.29%
20	Promoters and promoter group Shareholding											
	a) Pledged/Encumbered											
	- Number of Shares											
	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)											
	-	-	-	-	-	-	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)											
	-	-	-	-	-	-	-	-	-	-	-	-
	b) Non-encumbered											
	- Number of Shares											
	1,02,46,753	88,70,753	88,70,753	1,02,46,753	88,70,753	88,70,753	1,02,46,753	88,70,753	88,70,753	1,02,46,753	88,70,753	88,70,753
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)											
	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)											
	67.81%	58.71%	58.71%	67.81%	58.71%	58.71%	67.81%	58.71%	58.71%	67.81%	58.71%	58.71%
B	INVESTOR COMPLAINTS											
	3 months ended 31-3-2015											
	Pending at the beginning of the quarter											
	Nil											
	Received during the quarter											
	46											
	Disposed off during the quarter											
	46											
	Remaining unresolved at the end of the quarter											
	Nil											

Notes:

- 1) The Company operates in one segment only.
- 2) The above consolidated unaudited financial results were considered and recommended by the Audit Committee of the Board and have been approved by the Board of Directors at its meeting held on 12th May 2015
- 3) The statutory auditors have carried out a limited review of the results for the quarter ended 31st March 2015
- 4) The consolidated financial results include the financial results of Argus Salud Pharma LLP in which controlling interest is held by the company.
- 5) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai
Date : 12.05.2015


Dr. Sridhar Ganesan
Managing Director